VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Corvus Pharmaceuticals Executive Compensation (FY25)

CRVS · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Richard Miller
Latest say-on-pay support
=
June 11, 2026
Free for 3 days · no card

See how Corvus Pharmaceuticals’s pay stands against its peers

  • Corvus Pharmaceuticals's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRVSSee the plan and pricing
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Velarion Intel, $499/month, or $5,000/year, about two months free: one seat · every company we cover · 7-day refund, with dashboards, peer screens and board-ready briefs.

The Corvus Pharmaceuticals brief, $299

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $449.
Get the executive briefGet the board briefNo account needed.
Data as of November 11, 2026Latest filing (8-K): June 12, 2026
7 filings cited on this page
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
Corvus Pharmaceuticals brief$299Get the executive brief
Velarion Intel, one year, every company
124 figures on this page: 119 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Richard Miller: $3,073,170 → $7,031,566 (128.8% higher)
Say-on-pay support: 94.7% → 96.8% (2.1 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Corvus Pharmaceuticals' chief executive and what were they paid?
Richard Miller was paid $7,031,566 in total compensation as President and Chief Executive Officer for fiscal 2025. Miller's total moved 128.8% higher from the $3,073,170 reported for fiscal 2024.
What was Corvus Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.8% of votes cast for or against in favor at the meeting held June 11, 2026.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Miller
President and Chief Executive Officer
◇——◇——◇◇
Leiv Lea
Chief Financial Officer
◇——◇——◇◇
William Jones
Senior Vice President, Pharmaceutical Development
◇——◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Miller
President and Chief Executive Officer
◇——◇——◇◇
Leiv Lea
Chief Financial Officer
◇——◇——◇◇
William Jones
Senior Vice President, Pharmaceutical Development
◇——◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Miller
President and Chief Executive Officer
◇——◇——◇◇
Leiv Lea
Chief Financial Officer
◇——◇——◇◇
William Jones
Senior Vice President, Pharmaceutical Development
◇——◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Miller
President and Chief Executive Officer
◇——◇——◇◇
Leiv Lea
Chief Financial Officer
◇——◇——◇◇
William Jones
Senior Vice President, Pharmaceutical Development
◇——◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
William JonesRSU◇◇——
Option◇—◇12/3/2035
Option◇—◇12/19/2034
Option◇—◇12/5/2033
Option◇—◇8/10/2032
Richard MillerOption◇—◇12/3/2035
Option◇—◇12/19/2034
Option◇—◇12/5/2033
Option◇—◇3/30/2033
Option◇—◇8/10/2032
Leiv LeaOption◇—◇12/3/2035
Option◇—◇12/19/2034
Option◇—◇12/5/2033
Option◇—◇8/10/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David S. Moore
◇—◇———◇
Scott W. Morrison
◇—◇———◇
Richard van den Broek
◇—◇———◇
Linda S. Grais, M.D., J.D
◇—◇———◇
Peter A. Thompson, M.D
◇—◇———◇
Ian T. Clark
◇—◇———◇
Elisha P. (Terry) Gould III
◇—————◇
Richard A. Miller, M.D and Andrew C. Chan, M.D., Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2024June 12, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 15, 2022=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Richard Miller (President and Chief Executive Officer), FY2025 total compensation $7,031,566 (base salary $36,566) [exec_comp, SEC accession 0001104659-26-048595, filed 2026-04-24]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Corvus Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Corvus Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $299
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $299
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Corvus Pharmaceuticals' disclosed peer group is defensible, who names Corvus Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
124 figures on this page: 119 cited to the filing that reported them, 5 calculated from figures it prints.
119 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001171843-26-004094
    Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers On a non-binding advisory basis, the Company’s stockholders approved the compensation of
  2. 0001104659-26-048595
    DIRECTOR COMPENSATION · Outstanding Equity Awards at December 31, 2025 · Summary Compensation Table
  3. 0001171843-25-003881
    Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers On a non-binding advisory basis, the Company’s stockholders approved the compensation of
  4. 0001171843-24-003444
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001558370-24-005898
    Summary Compensation Table
  6. 0001171843-23-004019
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001171843-22-004406
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Corvus Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CRVS (accessed 2026).
Short form: data: Velarion

The Corvus Pharmaceuticals brief, $299

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $449.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Corvus Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy